Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Wilkins
M R
MR
Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, U.K.
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007189:Indans / Q000627:therapeutic use*; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011422:Propionates / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D015244:Thiorphan / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D003509:Cyclohexanecarboxylic Acids; D004232:Diuretics; D007189:Indans; D011422:Propionates; D011480:Protease Inhibitors; C049331:racecadotril; C060942:candoxatrilat; C062766:candoxatril; D015244:Thiorphan; D015260:Neprilysin